Are Mounjaro and Zepbound the same drug?

Yes — both are tirzepatide, manufactured by Eli Lilly. Mounjaro is labeled for type 2 diabetes and Zepbound is labeled for chronic weight management, but the molecule, injection device, and dose range (2.5 to 15 mg weekly) are identical. Stopping either produces the same transition.

How much weight is regained after stopping tirzepatide?

In the SURMOUNT-4 trial, participants who continued tirzepatide after a 36-week lead-in lost an additional 5.5% of body weight over the next year, while those switched to placebo regained about 14 percentage points — a roughly 20 percentage point swing driven entirely by removing the drug. 89.5% of the continued-treatment group maintained at least 80% of their lead-in weight loss at week 88, versus 16.6% of the placebo group.

How long does tirzepatide stay in your system?

Tirzepatide has a half-life of about 5 days — noticeably shorter than semaglutide's ~1 week. Near-complete drug clearance takes roughly 3–4 weeks after the last dose. Appetite rebound tends to arrive within 1–2 weeks, faster than the equivalent semaglutide transition.

Is stopping tirzepatide harder than stopping semaglutide?

The transition tends to be sharper because tirzepatide clears the system faster and produces stronger appetite suppression at maintenance doses. The SURMOUNT-4 rebound was larger and steeper than the equivalent semaglutide data in STEP-1. Same clinical framework applies — protein, structure, resistance activity — but the timing is compressed.

Do I need to taper off Mounjaro or Zepbound?

There is no FDA-labeled or WHO-recommended tapering protocol for tirzepatide. Some prescribers step down through the reverse titration schedule (15 → 12.5 → 10 → 7.5 → 5 → 2.5 mg); others stop directly. Because tirzepatide clears faster and rebounds harder, the argument for tapering may be marginally stronger than for semaglutide — but this is inference, not measured evidence.

Will I regain more weight on tirzepatide than semaglutide?

The one-year regain trajectory in SURMOUNT-4 was larger in absolute terms than the equivalent semaglutide numbers in STEP-1 extension — but participants also lost more weight during active treatment. As a percentage of loss, the regain patterns look broadly comparable. Both trials show the same shape: appetite return drives weight regain, and habit consistency is the largest source of individual variance.

Stopping Mounjaro or Zepbound: What to Expect

Written by the GLP-1 Coach editorial team. Last updated August 14, 2026.

Mounjaro and Zepbound are the same drug — tirzepatide, Eli Lilly's dual GIP/GLP-1 receptor agonist — sold under two brand names for two different indications. Mounjaro is labeled for type 2 diabetes; Zepbound is labeled for chronic weight management. The injection pen, the dose range, and the transition after stopping are identical.

Because tirzepatide clears the system faster than semaglutide and produces stronger appetite suppression at maintenance doses, stopping either brand tends to feel sharper and arrive faster than the equivalent semaglutide transition. Here's what the actual trial data shows.

What SURMOUNT-4 actually measured

The clearest dataset on stopping tirzepatide comes from the SURMOUNT-4 trial, published in JAMA in 2023. The design was different from a standard "on-drug vs placebo" comparison — it was a lead-in / withdrawal trial specifically built to isolate what happens when tirzepatide is stopped.

Design: All participants received tirzepatide (10 or 15 mg weekly) for a 36-week open-label lead-in, during which they lost an average of 20.9% of body weight. At week 36, they were randomly assigned either to continue tirzepatide or switch to placebo for the next 52 weeks.

Result at week 88:

	Continued tirzepatide	Switched to placebo
Additional weight change over 52 weeks	−5.5%	+14.0%
% retaining ≥80% of lead-in loss	89.5%	16.6%
Total weight change from baseline	−25.3%	−9.9%

The roughly 20 percentage point swing between the two groups over one year is the pure pharmacological contribution of tirzepatide, disentangled from any behavioral or habit differences established during the lead-in period.

Interpretation: removing tirzepatide reliably reverses a substantial portion of the weight loss it produced, on a timescale of months, in the absence of specific compensating structure.

Timeline of the transition after your last tirzepatide dose

Tirzepatide's ~5-day half-life means the drug clearance clock is meaningfully faster than semaglutide's:

Time since last dose	Approximate drug level	What most people notice
Day 5	~50% remaining	Slight uptick in hunger; GI side effects fading
Day 10	~25% remaining	Distinctly stronger hunger; ghrelin rebounding
Day 15	~12.5% remaining	Portion control less reliable; food noise returning
Day 20	~6% remaining	Appetite close to pre-treatment baseline
Day 25+	Functionally cleared	Habits are the primary protection

Compared to semaglutide's ~5-week clearance, tirzepatide is effectively "off" the system in 3–4 weeks. In practical terms this means the appetite rebound typically arrives one to two weeks earlier than it would after stopping Wegovy or Ozempic, and the compressed timeline can make the transition feel more abrupt.

The 1–3% weight uptick most people see in the first month is not fat regain — it's rehydration and stored carbohydrate returning as food volume rises back toward pre-treatment levels. Genuine regain, when it happens, tends to become visible in the trend line from about week 4–6 onward.

Why the tirzepatide rebound tends to be steeper than semaglutide's

Two mechanistic reasons the SURMOUNT-4 numbers are larger than the STEP-1 extension numbers:

First, tirzepatide produces more total weight loss during active treatment. Because the starting point of the regain curve is a larger absolute loss, the potential distance to regain is also larger. As a percentage of the loss achieved, the regain pattern is broadly comparable to semaglutide.

Second, appetite suppression on tirzepatide at 10–15 mg is typically stronger than on semaglutide 2.4 mg. This is likely due to the dual GIP/GLP-1 mechanism — tirzepatide activates both receptors, while semaglutide only activates GLP-1. When that stronger suppression is removed, the physiological "return to baseline" is a larger step.

The practical framing: tirzepatide gives more, and asks for more back if you stop. The habit structure carrying the loss forward matters at least as much as it would on semaglutide — arguably more, because the physiological gradient is steeper.

Does it matter if I was on Mounjaro (diabetes) vs Zepbound (weight management)?

No, from a drug-transition standpoint. Both are tirzepatide at the same dose range on the same titration schedule (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg). Whichever brand you were on, the pharmacokinetics, clearance timeline, and appetite-return curve are identical.

Where the two labels can produce different transitions is in the reason for stopping and the dose you were at. Zepbound users are more likely to be at higher weight-management doses (typically 10 or 15 mg). Mounjaro users may be at lower doses if the medication was adequately controlling A1C at 5, 7.5, or 10 mg. Absolute regain risk scales with total weight loss achieved, which scales with dose — so a Mounjaro user maintained on 5 mg has a different risk picture than a Zepbound user stopping at 15 mg, even though the underlying pharmacology is the same.

For diabetes patients specifically: what happens to blood sugar

If you were on Mounjaro for type 2 diabetes, tirzepatide cessation reverses the glucose-lowering effect as well as the weight-lowering effect. In diabetes-focused trials of both semaglutide and tirzepatide, HbA1c has consistently been shown to rise toward pre-treatment levels within weeks to months of discontinuation, in proportion to the glucose control the drug had been providing. The specific monitoring framework for blood sugar after stopping a GLP-1 is covered in blood sugar and A1C after stopping Ozempic: what to expect if you have type 2 diabetes.

This is a distinct issue from weight regain and generally warrants closer follow-up with your prescriber than a pure weight-management stop would. Specific rebound deltas (how much A1C rises, over what window) aren't well characterized in a dedicated withdrawal trial — the direction is well-supported, the exact magnitude is not.

Do I need to taper Mounjaro or Zepbound?

No FDA-labeled protocol exists. The WHO's December 2025 GLP-1 obesity guideline notes that discontinuation evidence is limited for the drug class overall.

Some prescribers step down through the reverse titration schedule:

Weeks	Dose
1–4	12.5 mg weekly (down from 15 mg)
5–8	10 mg weekly
9–12	7.5 mg weekly
13–16	5 mg weekly
17–20	2.5 mg weekly
21+	Discontinued

The argument for tapering may be marginally stronger for tirzepatide than for semaglutide, because the faster clearance and stronger appetite suppression mean the abrupt-stop rebound is sharper. But this is a physiological inference, not a measured outcome — no trial has shown that tapering tirzepatide changes the year-long regain trajectory compared to stopping directly.

If cost, coverage, and adherence favor tapering, it's reasonable. If any of those don't, stopping directly is not dangerous — SURMOUNT-4 itself used abrupt cessation and produced the regain data everyone cites.

What actually protects the weight loss

Two levers with the strongest support, unchanged from the semaglutide framework:

Protein target at 0.7–1 g per pound of goal body weight, consistent through the appetite-return window. The compressed tirzepatide clearance timeline makes this even more important — there's less runway to notice a slip and recover.
Resistance activity two or more times per week. Protects lean mass and metabolic rate while food volume climbs. Twice weekly is the standard minimum; three times weekly is closer to the evidence-supported range for meaningful preservation.

These aren't tirzepatide-specific interventions — they're the durable-outcome playbook for weight-cycling generally. The reason they matter so much is that regained weight tends to come back as fat rather than muscle without a specific protein-and-resistance effort — and the SURMOUNT-4 regain trajectory is steeper than the equivalent semaglutide curve, so the cost of skipping them is higher. For the broader post-medication transition, life after Ozempic: how to maintain weight loss after stopping applies equally to Mounjaro and Zepbound users.

The bottom line

Bottom line: Stopping tirzepatide (Mounjaro or Zepbound) produces a ~3–4 week drug clearance, a distinctly faster appetite rebound than semaglutide, and — per SURMOUNT-4 — a roughly 20 percentage point weight swing over one year vs continued treatment. The transition is sharper than the semaglutide equivalent because tirzepatide produces more total weight loss and stronger appetite suppression. Habit structure (protein, resistance activity, meal consistency) carries proportionally more of the durable outcome.

Related tool: our free post-therapy timeline calculator applies this data to your specific last-dose date.

Final Thoughts

SURMOUNT-4 is the closest thing to a controlled test of what tirzepatide is actually doing when it's on and what happens when it's removed. The ~20 percentage point gap between the two arms is a striking illustration of how much of the observed weight loss on the drug is drug-dependent, not habit-dependent. That framing cuts two ways:

It's a strong argument against complacency during active treatment. The habits built while the medication is doing the appetite work are the specific insurance policy against the SURMOUNT-4-style regain curve.
It's also a strong argument against treating discontinuation as a failure signal. A significant portion of tirzepatide's benefit is by design pharmacological — the drug is doing the work it was designed to do — and removing it produces the physiological response the trials themselves documented.

The right frame for stopping tirzepatide is roughly: "the drug did what it does; now the habits do what they do." Both parts of that sentence carry real weight. The people who protect their loss most reliably after stopping are generally the people who built the second half during the first half.

Related:

This article is educational and not a substitute for medical advice. Decisions about stopping, tapering, or continuing Mounjaro or Zepbound should be made with the prescriber managing your care.

Sources: Aronne et al., SURMOUNT-4, JAMA 2023; SURMOUNT-4 post hoc analysis, JAMA Internal Medicine 2025; Mounjaro prescribing information, Eli Lilly; Zepbound prescribing information, Eli Lilly; WHO Global Guideline on GLP-1 Medicines for Obesity, December 2025.